Clinical Trial Update: Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

View source ↗

Summary

A completed clinical trial evaluated acromegaly patients resistant to conventional doses of first-generation somatostatin ligands.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Sandostatin (Octreotide acetate)
• Somatuline (lanreotide)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Acromegaly | Status: COMPLETED